ストックスクリーナーアプリを入手
4.07
4.63%
0.18
アフターアワーズ：
4.07
前日終値:
$3.89
開ける：
$4.06
24時間の取引高:
142.83K
Relative Volume:
0.43
時価総額：
$192.43M
収益：
$84.82M
当期純損益:
$-21.43M
株価収益率:
-8.3061
EPS:
-0.49
ネットキャッシュフロー:
$-27.23M
1週間 パフォーマンス:
-4.24%
1か月 パフォーマンス:
-15.73%
6か月 パフォーマンス:
-69.12%
1年 パフォーマンス:
-66.86%
1日の値動き範囲:
$3.94
$4.18
1週間の範囲:
$3.76
$4.46
52週間の値動き範囲:
$3.76
$16.11
Y Mabs Therapeutics Inc Stock (YMAB) Company Profile
名前
Y Mabs Therapeutics Inc
セクター
電話
646-885-8505
住所
202 CARNEGIE CENTER, PRINCETON, NY
YMAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
YMAB
Y Mabs Therapeutics Inc
|
4.07 | 192.43M | 84.82M | -21.43M | -27.23M | -0.49 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.37 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
575.63 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
560.90 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
270.19 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
233.25 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Y Mabs Therapeutics Inc Stock (YMAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-04-22 | ダウングレード | BofA Securities | Neutral → Underperform |
| 2024-11-18 | 開始されました | Oppenheimer | Outperform |
| 2024-08-16 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-06-28 | 開始されました | Truist | Buy |
| 2023-05-10 | アップグレード | Wedbush | Neutral → Outperform |
| 2023-04-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2023-01-27 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-01-05 | ダウングレード | Cowen | Outperform → Market Perform |
| 2022-12-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2022-10-31 | ダウングレード | JP Morgan | Neutral → Underweight |
| 2022-10-31 | ダウングレード | Wedbush | Outperform → Neutral |
| 2022-07-06 | 再開されました | Canaccord Genuity | Buy |
| 2022-06-24 | 開始されました | BMO Capital Markets | Outperform |
| 2022-02-03 | 再開されました | Guggenheim | Buy |
| 2021-11-19 | 再開されました | Morgan Stanley | Equal-Weight |
| 2021-11-16 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-05-07 | アップグレード | BofA Securities | Neutral → Buy |
| 2021-04-23 | 再開されました | Cowen | Outperform |
| 2021-03-22 | 再開されました | JP Morgan | Overweight |
| 2021-01-15 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-11-09 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-05-05 | 開始されました | Barclays | Overweight |
| 2020-05-01 | 開始されました | Janney | Buy |
| 2020-04-29 | 開始されました | Morgan Stanley | Equal-Weight |
| 2019-12-24 | 開始されました | JP Morgan | Overweight |
| 2019-11-20 | 開始されました | Guggenheim | Buy |
| 2019-09-04 | 開始されました | Wedbush | Outperform |
| 2019-04-01 | 開始されました | H.C. Wainwright | Buy |
| 2018-10-16 | 開始されました | BTIG Research | Buy |
| 2018-10-16 | 開始されました | BofA/Merrill | Buy |
すべてを表示
Y Mabs Therapeutics Inc (YMAB) 最新ニュース
Wells Fargo & Company MN Boosts Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Barclays PLC Purchases 6,640 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs gets NCCN recommendation for neuroblastoma treatment - MSN
Naxitamab Therapy Gains NCCN Support for Neuroblastoma By Investing.com - Investing.com Nigeria
Y-mAbs neuroblastoma drug endorsed by NCCN (YMAB:NASDAQ) - Seeking Alpha
Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®) - The Manila Times
Cancer Treatment Pioneer Y-mAbs Announces Q1 2025 Earnings Date: Key Updates Coming May 13 - Stock Titan
Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025 - The Manila Times
Y-mAbs Therapeutics, Inc. Scheduled to Report Q1 2025 Financial Results on May 13, 2025 - Nasdaq
Short Interest in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Drops By 16.1% - Defense World
Legal & General Group Plc Decreases Stock Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Renaissance Technologies LLC Raises Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Earnings Preview: Y-mAbs Therapeutics, Inc. (YMAB) Q1 Earnings Expected to Decline - Yahoo Finance
Insufficient Growth At Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Hampers Share Price - simplywall.st
JPMorgan Chase & Co. Raises Stock Holdings in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics (YMAB) Showcases CD38-SADA Data at AACR 2025 - GuruFocus
Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting - The Manila Times
Y-mAbs Therapeutics Presents Preclinical Data on CD38-SADA at 2025 AACR Annual Meeting - Nasdaq
Revolutionary Cancer Treatment: Y-mAbs CD38-SADA Therapy Achieves 20X Faster Clearance Rate in Latest Trial - Stock Titan
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) latest 13% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance
Press Release Distribution & PR Platform - ACCESS Newswire
Geode Capital Management LLC Has $6.44 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Q1 EPS Forecast for Y-mAbs Therapeutics Reduced by Analyst - Defense World
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment - Investing.com
Y-mAbs begins trial for new non-Hodgkin Lymphoma treatment By Investing.com - Investing.com India
Y-mAbs Therapeutics (YMAB) Begins Phase 1 Trial for Non-Hodgkin - GuruFocus
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma - The Manila Times
Y-mAbs announces first patient dosed in Phase 1 trial of CD38-SADA PRIT platform - TipRanks
Y-mAbs Therapeutics Initiates Phase 1 Trial of CD38-SADA Pre-targeted Radioimmunotherapy for Relapsed or Refractory Non-Hodgkin Lymphoma - Nasdaq
Groundbreaking Radioimmunotherapy: Y-mAbs Launches First-in-Human Trial for Advanced Lymphoma Treatment - Stock Titan
When the Price of (YMAB) Talks, People Listen - news.stocktradersdaily.com
Y-mAbs (YMAB) Faces Downgrade as Market Potential Wanes - GuruFocus
Y-mAbs drops as Bank of America downgrades on headwinds to Danyelza - MSN
ITeos Therapeutics Inc (ITOS) Stock: From Low to High in 52 Weeks - investchronicle.com
Y-Mabs Therapeutics Inc Inc. (YMAB) Price Performance: The Role of Supply and Demand - investchronicle.com
Y-Mabs Therapeutics Inc (YMAB) stock: A year of ups and downs - uspostnews.com
Ratio Review: Analyzing Y-Mabs Therapeutics Inc (YMAB)’s Price-to-Cash and Price-to-Free Cash Flow - DWinneX
Y-mAbs Therapeutics (NASDAQ:YMAB) Downgraded by Bank of America to “Underperform” - Defense World
Y-mAbs stock down as Bank of America downgrades (YMAB:NASDAQ) - Seeking Alpha
BofA cuts YMAB stock rating to underperform, slashes target to $3 - Investing.com
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Short Interest Update - Defense World
Vanguard Group Inc. Trims Stake in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Wellington Management Group LLP Sells 3,451 Shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
ExodusPoint Capital Management LP Buys New Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - The AM Reporter
KLP Kapitalforvaltning AS Acquires New Shares in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Prudential Financial Inc. Lowers Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) - Defense World
Y-mAbs Therapeutics: A Yawn From The Market Means Opportunity (YMAB) - Seeking Alpha
Investing in Oncology: 4 Companies Driving Cancer Treatment Innovation - openPR.com
YMAB LAWSUIT: Hagens Berman, National Trial Attorneys, Encourages Y-mAbs Therapeutics (YMAB) Investors with Significant Losses to Contact the Firm’s Attorneys, Securities Fraud Class Action Filed - ACCESS Newswire
Pediatric Neuroblastoma Treatment Market Size in 7MM - openPR.com
Y Mabs Therapeutics Inc (YMAB) 財務データ
収益
当期純利益
現金流量
EPS
4.10%
大文字化:
|
ボリューム (24 時間):